At Biosfer Teslab, we continue to expand our international presence thanks to the support of ACCIÓ, which has enabled us to drive growth and consolidate the Liposcale® test in new markets. Through the grant for international promotion activities, we have developed innovative digital tools that facilitate collaboration with international laboratories and ensure the highest quality in our services.
Additionally, we have launched email marketing campaigns aimed at introducing Liposcale® into the global clinical trials market, further strengthening our presence and impact in the international biomedical sector.
In addition, we have developed a quality control software integrated into our platform, designed to ensure maximum accuracy in spectrum analysis. This tool automatically validates the obtained spectra, detecting potential deviations and ensuring that results meet international quality and reliability standards.
Thanks to its automation capabilities and intelligent data filtering, the system significantly reduces the risk of errors in result interpretation and optimizes analysis times. This not only enhances the efficiency of collaborating laboratories but also facilitates the adoption of the Liposcale® test in new markets, ensuring a faster, safer, and standardized process at the international level.
With the support of ACCIÓ, we have also carried out a series of strategic digital marketing actions and international advertising campaigns, with a primary focus on the European market. These initiatives have been key in boosting our global visibility, strengthening Biosfer Teslab’s presence in the biotech sector, and increasing recognition of the Liposcale® test as an innovative tool in lipoprotein analysis.
Through targeted campaigns, we have successfully reached researchers, research centers, and healthcare professionals, highlighting the benefits of the Liposcale® test and its application in advanced clinical studies. Additionally, by optimizing our digital strategies, we have strengthened our presence on specialized platforms and scientific networks, making relevant information more accessible to potential collaborators and clients.
These efforts have led to new connections with leading researchers and institutions, opening up opportunities for the integration of the Liposcale® test into innovative clinical trials. This initiative not only drives Biosfer Teslab’s international growth but also reinforces our commitment to biomedical research and the personalization of cardiovascular diagnostics on a global scale.
This project has been a decisive step in our internationalization strategy, allowing us to expand into new markets and strengthen our position as a global leader in metabolomic and lipoprotein analysis. The combination of technological innovation, digitalization, and scientific collaboration has been key to advancing our mission of delivering cutting-edge solutions for biomedical research and healthcare.
We want to express our gratitude to ACCIÓ for their support in this process, which has enabled us to develop innovative digital tools, optimize our services, and strengthen our international presence. Thanks to this collaboration, we have been able to drive new business opportunities, consolidate strategic partnerships, and bring Biosfer Teslab’s technology closer to more professionals and institutions worldwide.
We remain committed to taking our technology to the next level, continuously developing more advanced solutions that contribute to scientific progress and the improvement of global health.
